Hepatitis C, Chronic: Clinical Trials

144 trials for Hepatitis C, Chronic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

100 completed, 21 unknown, 16 terminated, 5 withdrawn. 144 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4144Completed 100, Unknown 21, Terminated 16, Withdrawn 5, Active not recruiting 2

Follow Hepatitis C, Chronic: new trials by email Literature Review of Hepatitis C, Chronic trials Research Report on Hepatitis C, Chronic

Trials (filtered) newest first · largest first

All 144 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet - Hepatitis C, Chronic, Pregnancy; Infection
Phase 4Active not recruitingCatherine Anne Chappell1002022-04-042026-10-19
The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China
Tenofovir Alafenamide 25 MG, Sofosbuvir / Velpatasvir - Chronic Hepatitis C, Chronic Hepatitis B
Phase 4UnknownPeking University First Hospital1202021-08-012021-08-09
Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders
Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin, Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] - Chronic Hepatitis C
Phase 4CompletedHelwan University2812020-11-212022-09-02
Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] - End Stage Renal Disease, Chronic Hepatitis c
Phase 4WithdrawnMassachusetts General Hospital2020-11-132022-03-08
The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study
Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus - Hepatitis C, Chronic
Phase 4CompletedUniversity of California, San Francisco872020-07-012025-05-28
Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)
sofosbubir/velpatasvir, sofosbubir/velpatasvir/voxilaprevir - Hepatitis C, Chronic
Phase 4UnknownPartners in Health1002019-08-262019-09-11
ATTIC - Access To Treat in the Community
ZEPATIER 50Mg-100Mg Tablet - Hepatitis C, Chronic
Phase 4TerminatedKing's College Hospital NHS Trust132019-03-232023-05-06
Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation
grazoprevir 100 mg/ elbasvir 50 mg, Zepatier® - Chronic Hepatitis c, Liver Transplant Infection
Phase 4TerminatedTaichung Veterans General Hospital142019-02-142021-03-16
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Epclusa - Diabetes Mellitus, Hepatitis C, Chronic
Phase 4Active not recruitingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1212018-10-192026-10-22
Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics
velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) . - Chronic Hepatitis C, People Who Inject Drugs
Phase 4UnknownCenter For Hepatitis C, Atlanta, GA1252018-03-012023-06-08
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
Genvoya, Epclusa, Biktarvy - HIV-1-infection, Hepatitis C, Chronic
Phase 4UnknownSaskatchewan Health Authority - Regina Area252018-02-012019-12-24
Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection
Sofosbuvir/Velpatasvir - Hepatitis C, Chronic, Opioid-use Disorder
Phase 4CompletedElizabeth Krans, MD322018-01-302023-05-06
MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV
OBV/PTV/r and DSV, Placebo to match OBV/PTV/r and DSV - Hepatitis C, Chronic
Phase 4TerminatedHannover Medical School52017-10-242023-08-14
Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection
grazoprevir and elbasvir - Chronic Hepatitis C
Phase 4CompletedTaoyuan General Hospital402017-10-202018-12-20
A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic
sofosbuvir/velpatasvir - Hepatitis C, Chronic, Hepatitis C
Phase 4CompletedCommunity Research Initiative of New England112017-10-112021-05-13
Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment
Epclusa - Hepatitis C, Chronic, Lung Transplant
Phase 4TerminatedDuke University12017-09-152019-09-11
Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir
Sofosbuvir 400 mg and daclatasvir 60 mg - Hepatitis C, Chronic, Chronic Renal Failure
Phase 4CompletedTehran University of Medical Sciences952017-04-012019-09-30
Curing HCV in Incarcerated Patients
Patients receiving Sof/Vel (Epclusa) and Navigation services - Hepatitis C, Chronic
Phase 4UnknownSan Francisco Department of Public Health1002017-03-052017-06-01
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Viekira Pak ± ribavirin, Mavyret - Chronic Kidney Disease, Chronic Hepatitis C
Phase 4CompletedMassachusetts General Hospital102017-02-012021-11-05
Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C
elbasvir, grazoprevir - Chronic Hepatitis C
Phase 4UnknownNorte Study Group602017-01-152017-04-12

Showing 20 of 144. Sign in to see all of them.

Narrower conditions

Hepatitis C (34)  ·  HIV Infections (7)  ·  Carcinoma, Hepatocellular (4)  ·  Coinfection (4)  ·  Fibrosis (4)  ·  Hepatitis (4)  ·  Insulin Resistance (4)  ·  Kidney Failure, Chronic (4)  ·  Opioid-Related Disorders (4)  ·  Acquired Immunodeficiency Syndrome (3)  ·  Hepatitis, Chronic (3)  ·  Recurrence (3)  ·  Anemia, Hemolytic (2)  ·  Bone Diseases, Metabolic (2)

Broader conditions

Blood-Borne Infections (144)  ·  Chronic Disease (144)  ·  Communicable Diseases (144)  ·  Digestive System Diseases (144)  ·  Disease Attributes (144)  ·  Infections (144)  ·  Pathologic Processes (144)  ·  Pathological Conditions, Signs and Symptoms (144)  ·  Flaviviridae Infections (143)  ·  Hepatitis, Viral, Human (143)  ·  RNA Virus Infections (143)  ·  Virus Diseases (143)  ·  Liver Diseases (142)  ·  Hepatitis, Chronic (141)  ·  Hepatitis (140)

Interventions

Ribavirin (85)  ·  peginterferon alfa-2a (65)  ·  peginterferon alfa-2b (18)  ·  Sofosbuvir (11)  ·  sofosbuvir-velpatasvir drug combination (10)  ·  N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (4)  ·  elbasvir-grazoprevir drug combination (4)  ·  ledipasvir (4)  ·  ledipasvir, sofosbuvir drug combination (4)  ·  velpatasvir (4)  ·  Metformin (3)  ·  Pioglitazone (3)  ·  Simeprevir (3)  ·  daclatasvir (3)  ·  dasabuvir (3)

Sponsors

Hoffmann-La Roche (28)  ·  Merck Sharp & Dohme LLC (7)  ·  Kaohsiung Medical University Chung-Ho Memorial Hospital (6)  ·  National Taiwan University Hospital (6)  ·  Kirby Institute (5)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3)  ·  Center For Hepatitis C, Atlanta, GA (2)  ·  Duke University (2)  ·  Federal University of São Paulo (2)  ·  Göteborg University (2)  ·  Hospital Carlos III, Madrid (2)  ·  King Abdulaziz Medical City (2)  ·  Massachusetts General Hospital (2)  ·  MinaPharm Pharmaceuticals (2)  ·  Partners in Health (2)

Countries

United States (38)  ·  Taiwan (15)  ·  Spain (12)  ·  Germany (10)  ·  Canada (9)  ·  Australia (8)  ·  Brazil (8)  ·  Italy (7)  ·  South Korea (7)  ·  France (6)  ·  Sweden (6)  ·  Austria (5)  ·  Egypt (5)  ·  Puerto Rico (5)  ·  United Kingdom (5)

Top investigators

Ming-Lung Yu, MD, PhD (5)  ·  Chen-Hua Liu, MD (4)  ·  Ding-Shinn Chen, MD (3)  ·  Jee-Fu Huang, MD (3)  ·  Chang-Fu Chiu, MD (2)  ·  Cheng-Chao Liang, MD (2)  ·  Chia-Yen Dai, MD, Ms (2)  ·  Chih-Lin Lin, MD (2)  ·  Ching-Sheng Hsu, MD (2)  ·  Chun-Jen Liu, MD, PhD (2)  ·  Fred Poordad, MD (2)  ·  Gamal Esmat, MD (2)  ·  Gregory Dore, MBBS, PhD (2)  ·  Jia-Horng Kao, MD, PhD (2)

Results publications

PMID 26867206, PMID 30552056, PMID 37096802, PMID 17625124, PMID 17875007, PMID 17943989, PMID 18081737, PMID 18508296, PMID 18684176, PMID 18834319, PMID 19144941, PMID 19628656, PMID 20102281, PMID 20377423, PMID 20816836, PMID 21064034, PMID 21205057, PMID 21281434, PMID 21439960, PMID 21506241, PMID 21714878, PMID 21784046, PMID 22235243, PMID 22592094, PMID 23428875, PMID 23442834, PMID 23593611, PMID 23795661, PMID 23884073, PMID 24073301, PMID 24297189, PMID 24360571, PMID 24747867, PMID 25557952, PMID 25909356, PMID 26057627, PMID 26094738, PMID 26130141, PMID 26327916, PMID 27228998, PMID 27720838, PMID 28193518, PMID 28358734, PMID 28539950, PMID 28586923, PMID 28610605, PMID 29316001, PMID 29906601, PMID 31114268, PMID 31158245

NIH funding

2005 (4), 2004 (2), 2015 (1), R01DA013806 (1)